FXR agonist compositions for combination therapy
AssigneeIntercept Pharmaceuticals, Inc.
InventorsMark Pruzanski, Luciano Adorini
Life of this patent
Estimating the term…
Abstract
The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.
Claims8
A pharmaceutical composition comprising an FXR agonist, at least one additional therapeutic agent, and optionally one or more pharmaceutically acceptable carriers, wherein the FXR agonist is a compound of formula I:
- or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein:
- R1 is hydrogen or unsubstituted C1-C6 alkyl;
- R2 is hydrogen or α-hydroxyl;
- R4 is hydroxyl or hydrogen;
- and
- R7 is hydroxyl or hydrogen,
- wherein the at least one additional therapeutic agent is a GLP-1 receptor agonist selected from exenatide/exendin-4, liraglutide, taspoglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, BRX-0585 (Pfizer/Biorexis), and CJC-1134-PC (exendin-4 conjugated to human albumin), wherein the pharmaceutical composition is in a form for oral administration.
Dependencies are inferred from the claim text.